Nuvalent advances with $1.37B cash, targeting 2026 drug approvals in precision oncology.

Nuvalent is a late-stage biotech firm with strong financial backing, holding $1.37 billion in cash plus a recent $500 million raise to fund operations through 2029. It focuses on precision oncology with two near-commercial drugs: zidesamtinib, whose NDA for ROS1-positive NSCLC was accepted with a PDUFA date set for September 2026, and neladalkib, planned for NDA submission in the first half of 2026. The company aims to disrupt the competitive tyrosine kinase inhibitor market by addressing resistance, CNS activity, and tolerability, targeting significant unmet medical needs in thoracic oncology.